First Savings Financial Group, Inc. (NASDAQ:FSFG) shares increased 0.09% in last trading session and ended the day at $33.91. Its has a return on assets of 0.90%. First Savings Financial Group, Inc. (NASDAQ:FSFG) quarterly performance is 15.59%.
First Savings Financial Group, Inc. (NASDAQ:FSFG) reports preliminary financial results for the quarter ended June 30, 2015. Revenues of USD 7.13 million, Net Earnings of USD 2.20 million, and Earnings per Share (EPS) of USD 0.95. Net interest income margins widened from 83.29% to 85.62% compared to the same quarter last year.
Full House Resorts Inc. (NASDAQ:FLL) ended the last trading day at $1.44. Company weekly volatility is calculated as 10.40% and price to cash ratio as 1.89. Full House Resorts Inc. (NASDAQ:FLL) showed a weekly performance of -1.37%.
Gaming is big business in Cripple Creek, and now a $30-million deal is in the works to buy one of the most prominent casinos there. Las Vegas-based Full House Resorts Inc. (NASDAQ:FLL) is planning to buy Bronco Billy’s Casino and Hotel, which is one of the last of the original casinos in Cripple Creek that is still locally owned. According to KOAA-TV, other local casinos closed down or were bought out by bigger companies because they struggled to navigate the gaming regulations and fines.
On 07 October, Brookline Bancorp, Inc. (NASDAQ:BRKL) shares increased 2.12% and was closed at $10.60. BRKL EPS growth in last 5 year was 13.40%. Brookline Bancorp, Inc. (NASDAQ:BRKL) year to date (YTD) performance is 8.39%.
Brookline Bancorp, Inc. (NASDAQ:BRKL) announced that it will report third quarter 2015 earnings at the close of business on Wednesday, October 21, 2015. Management will host a conference call to review this information at 1:30 PM Eastern Time on Thursday, October 22, 2015.
CorMedix, Inc. (NYSEMKT:CRMD) shares increased 6.19% in last trading session and ended the day at $2.40. CRMD Gross Margin is -33.30% and its has a return on assets of -111.10%. CorMedix, Inc. (NYSEMKT:CRMD) quarterly performance is -33.70%.
CorMedix Inc. (NYSE MKT: CRMD), announced highlights from two sponsored abstracts for poster presentation at the American Society of Nephrology Kidney Week 2015. The data to be presented highlight the potential cost savings from reducing infections and thrombosis in hemodialysis patients with central venous catheters (CVCs). Complications from long-term catheter use can lead to treatment delays and increased costs to the healthcare system due to hospitalizations, need for additional treatment, and/or removal or replacement of the catheter,” said Randy Milby, CEO, CorMedix. “CorMedix is proud to sponsor the abstracts, prepared by DaVita Clinical Research, which highlight the potential cost savings to providers and payers from reducing complications in hemodialysis patients with CVCs. We look forward to presenting the full data at the American Society of Nephrology Kidney Week meeting next month.
CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD) caters to the Healthcare space. Its weekly performance is 13.95%. On the last day of trading company shares ended up at $4.41. CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD) distance from 50-day simple moving average (SMA50) is -33.94%.
Zacks upgraded shares of CoLucid Pharmaceuticals (NASDAQ:CLCD) from a sell rating to a hold rating in a report published on Thursday.
Leave a Reply